Articles By RheumNow
Targeting the Wnt Pathway Fails in OA
By RheumNow
The Wnt pathway modulator lorecivivint failed to meet the primary endpoint in a phase IIa study for knee osteoarthritis (OA), but showed promise in certain patient subgroups, researchers reported.
Read Article
Anti-TNF and CNS Events: The Link Strengthens
By RheumNow
Patients with autoimmune diseases who were treated with tumor necrosis factor (TNF) inhibitors had an increased risk of developing inflammatory central nervous system (CNS) adverse events, a nested case-control study found.
Read Article
Kids' COVID-Linked Ailment Is Not Your Typical Kawasaki Disease
By RheumNow
As data continue to emerge about a multi-system inflammatory disorder in children apparently connected to COVID-19, evidence is growing that this is not your typical Kawasaki disease.
Read Article
Biologic Dose Cuts Feasible in RA
By RheumNow
Many patients with rheumatoid arthritis (RA) who achieved remission or low disease activity on biologic treatment were able to reduce the dose of their biologic, particularly if they were also on methotrexate, a retrospective study found.
Read Article
Lenabasum Encouraging in Systemic Sclerosis
By RheumNow
The oral cannabinoid receptor type 2 (CB2) agonist lenabasum showed promising results for systemic sclerosis (SSc) in a phase II study.
Read Article
COVID-19 and the Slippery Road of Cytokine Storms
By RheumNow
Early reports on the COVID-19 pandemic allude to a cytokine storm or hyper-inflammation, especially in patients who succumbed to the illness.
Read Article
Lower Risk of Diabetes with Abatacept
By RheumNow
Patients with rheumatoid arthritis (RA) treated with abatacept (Orencia) had a lower risk of developing diabetes mellitus compared with those receiving certain tumor necrosis factor (TNF) inhibitors, a large cohort study suggested.
Read ArticleGuselkumab a Hit in Phase III for PsA
By RheumNow
The monoclonal antibody guselkumab (Tremfya), which binds the interleukin (IL)-23 p19 subunit, was effective for psoriatic arthritis in two large clinical trials, providing comprehensive benefits for this heterogeneous disorder, investigators reported in The Lancet.
Read Article
Tanezumab: A Win as Last-Ditch Osteoarthritis Tx
By RheumNow
A phase III study of the nerve growth factor and monoclonal antibody tanezumab showed positive results in a refractory patient population with knee or hip osteoarthritis (OA) -- good enough that this agent may finally be approved after a long and rocky development road.
Read Article
COVID-19 Susceptibility: Why Do Some Become So Ill?
By RheumNow
The differential susceptibility to COVID-19 infection is attributable to socioeconomic factors and genetic differences, that together with environmental factors, human-virus interactions, gender, perhaps blood type, and age-related senescence determine the immune response and the likelihood of developing disease.
Read Article